AmCad BioMed Corporation (TPEX:4188)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.00
+0.05 (0.39%)
Mar 10, 2026, 9:15 AM CST
-35.48%
Market Cap 820.16M
Revenue (ttm) 30.44M
Net Income (ttm) -55.72M
Shares Out 63.33M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,000
Average Volume 41,088
Open 13.05
Previous Close 12.95
Day's Range 13.00 - 13.10
52-Week Range 12.30 - 20.00
Beta 0.34
RSI 28.60
Earnings Date Feb 26, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2008
Employees 34
Stock Exchange Taipei Exchange
Ticker Symbol 4188
Full Company Profile

Financial Performance

In 2025, AmCad BioMed's revenue was 30.44 million, a decrease of -42.69% compared to the previous year's 53.11 million. Losses were -55.72 million, 10.2% more than in 2024.

Financial Statements

News

There is no news available yet.